Uterotonic Prophylaxis Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hemorrhage
Interventions
DRUG

Methergine

0.2 mg of methylergonovine maleate

OTHER

placebo

saline placebo to maintain blinding

Trial Locations (1)

94110

SFGH Women's Options Center, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02408965 - Uterotonic Prophylaxis Trial | Biotech Hunter | Biotech Hunter